ALLO News and Press, Allogene Therapeutics Inc. From 03/14/24

2024-03-14 16:24:11 ET More on Allogene Therapeutics Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead Allogene Therapeutics Q4 2023 Earnings Preview Allogene drops on layoffs and pipeline reorganization (update) Seeking Alpha’...

Cema-cel Pivotal ALPHA3 First Line (1L) Consolidation Trial in Large B-Cell Lymphoma (LBCL) : Start-Up Activities Underway; Enrollment to Begin Mid-2024 Cema-cel Phase 1 ALPHA2 Trial in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Enrolling Patients with Initial Dat...

AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...

2024-03-13 17:35:32 ET Major earnings expected after the bell on Thursday include: Adobe ( ADBE ) Wheaton Precious Metals Corp. ( WPM ) Ulta Beauty ( ULTA ) Skillz ( SKLZ ) Blink Charging Co. ( BLNK ) Read the full article on Seeking Alpha ...

2024-03-13 17:35:09 ET More on Allogene Therapeutics Allogene Therapeutics: A Promising Biotech With A Concerning Lag Time Ahead Allogene drops on layoffs and pipeline reorganization (update) Seeking Alpha’s Quant Rating on Allogene Therapeutics Histor...

Allogene’s AlloCAR T™ Autoimmune Disease Platform Leverages Arbor’s CRISPR Gene-Editing Technology First Allogeneic CAR T Phase 1 Clinical Trial in Autoimmune Disease Expected to Initiate in Early 2025 SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, Mass., March 12, 20...

2024-03-11 05:50:46 ET More on related stocks: Oracle Q3 Earnings Preview: Cloud Computing Business In Focus Blink Charging: EV Tailwinds Offer A Path To Profitability In 2025 Ulta Beauty: We Are Not Adding To Our Position Before The Earnings Release (Rating Downgrad...

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will ...

Carisma Therapeutics Inc. (CARM) is expected to report $-0.56 for Q4 2023 First Acceptance Corp. (FACO) is expected to report for quarter end 2023-12-31 Bell Copper Corp (BCUFF) is expected to report for quarter end 2023-12-31 BioHarvest Sciences Inc (CNVCF) is expected to report for ...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will partic...